Literature DB >> 24141179

Effects of chronic exercise and treatment with the antipsychotic drug olanzapine on hippocampal volume in adult female rats.

A M Barr1, C H Wu, C Wong, C Hercher, E Töpfer, H N Boyda, R M Procyshyn, W G Honer, C L Beasley.   

Abstract

Numerous studies have reported that the hippocampus in schizophrenia patients is reduced in volume compared to the normal population. Antipsychotic medications have had mixed benefits in maintaining hippocampal volume or reversing volume loss. Recent evidence indicates that routine aerobic exercise represents a promising intervention for reversing hippocampal loss and cognitive deficits. In the present study, we measured the effects of chronic treatment with olanzapine and daily exercise on the hippocampal volumes of rats. Adult female rats were treated during the week with either olanzapine (10mg/kg) or vehicle for 9 consecutive weeks. Subgroups of animals were provided access to exercise running wheels for 1 or 3h per day during the same period, or were sedentary. Metabolic indices, including glucose tolerance, were measured on a weekly basis. At the conclusion of the study, brains were perfused and hippocampal sections were Nissl stained. Total hippocampal volume was measured using the Cavalieri estimator. Treatment with olanzapine caused a significant decrease in hippocampal volume in sedentary rats. However, exercise was able to reverse most of this volume loss. The hippocampal sub-regions of the dentate gyrus and CA1 were most strongly affected by olanzapine and exercise. Of interest, there was a strong and highly significant negative correlation between glucose intolerance and hippocampal volume, whereby greater glucose intolerance was associated with a smaller hippocampal volume. These findings indicate that exercise may have beneficial effects on the hippocampus when antipsychotic medication can contribute to changes in volume.
Copyright © 2013 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  ANOVA; AUC; CA1; IGTT; MRI; NIH; National Institutes of Health; SEM; analysis of variance; area-under-the-curve value; dentate gyrus; glucose intolerance; i.p.; intraperitoneal; intraperitoneal glucose tolerance test; magnetic resonance imaging; s.c.; second generation antipsychotic; standard error of the mean; stereology; subcutaneous

Mesh:

Substances:

Year:  2013        PMID: 24141179     DOI: 10.1016/j.neuroscience.2013.10.010

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  10 in total

1.  Genetic variability to diet-induced hippocampal dysfunction in BXD recombinant inbred (RI) mouse strains.

Authors:  Yueqiang Xue; JingJing Li; Lei Yan; Lu Lu; Francesca-Fang Liao
Journal:  Behav Brain Res       Date:  2015-06-16       Impact factor: 3.332

2.  Association Between Hippocampal Subfields and Clinical Symptoms of First-Episode and Drug Naive Schizophrenia Patients During 12 Weeks of Risperidone Treatment.

Authors:  Xiaoe Lang; Dongmei Wang; Dachun Chen; Meihong Xiu; Huixia Zhou; Li Wang; Bo Cao; Xiangyang Zhang
Journal:  Neurotherapeutics       Date:  2022-01-31       Impact factor: 6.088

3.  NeuN+ neuronal nuclei in non-human primate prefrontal cortex and subcortical white matter after clozapine exposure.

Authors:  Tobias B Halene; Alexey Kozlenkov; Yan Jiang; Amanda C Mitchell; Behnam Javidfar; Aslihan Dincer; Royce Park; Jennifer Wiseman; Paula L Croxson; Eustathia Lela Giannaris; Patrick R Hof; Panos Roussos; Stella Dracheva; Scott E Hemby; Schahram Akbarian
Journal:  Schizophr Res       Date:  2016-01-06       Impact factor: 4.939

4.  Loss of Munc18-1 long splice variant in GABAergic terminals is associated with cognitive decline and increased risk of dementia in a community sample.

Authors:  Alfredo Ramos-Miguel; Christa Hercher; Clare L Beasley; Alasdair M Barr; Thomas A Bayer; Peter Falkai; Sue E Leurgans; Julie A Schneider; David A Bennett; William G Honer
Journal:  Mol Neurodegener       Date:  2015-12-02       Impact factor: 14.195

5.  An evaluation of the effects of the novel antipsychotic drug lurasidone on glucose tolerance and insulin resistance: a comparison with olanzapine.

Authors:  Claire Wu; Jessica Yuen; Heidi N Boyda; Ric M Procyshyn; Cathy K Wang; Yahya I Asiri; Catherine C Y Pang; William G Honer; Alasdair M Barr
Journal:  PLoS One       Date:  2014-09-25       Impact factor: 3.240

6.  Polygenic risk has an impact on the structural plasticity of hippocampal subfields during aerobic exercise combined with cognitive remediation in multi-episode schizophrenia.

Authors:  S Papiol; D Popovic; D Keeser; A Hasan; T Schneider-Axmann; F Degenhardt; M J Rossner; H Bickeböller; A Schmitt; P Falkai; B Malchow
Journal:  Transl Psychiatry       Date:  2017-06-27       Impact factor: 6.222

7.  Lack of Social Support Raises Stress Vulnerability in Rats with a History of Ancestral Stress.

Authors:  Jamshid Faraji; Nabiollah Soltanpour; Hamid Lotfi; Reza Moeeini; Ali-Reza Moharreri; Shabnam Roudaki; S Abedin Hosseini; David M Olson; Ali-Akbar Abdollahi; Nasrin Soltanpour; Majid H Mohajerani; Gerlinde A S Metz
Journal:  Sci Rep       Date:  2017-07-13       Impact factor: 4.379

8.  Improving metabolic and cardiovascular health at an early psychosis intervention program in vancouver, Canada.

Authors:  Diane H Fredrikson; Heidi N Boyda; Lurdes Tse; Zachary Whitney; Mark A Pattison; Fred J Ott; Laura Hansen; Alasdair M Barr
Journal:  Front Psychiatry       Date:  2014-09-05       Impact factor: 4.157

Review 9.  Aerobic Exercise as a Tool to Improve Hippocampal Plasticity and Function in Humans: Practical Implications for Mental Health Treatment.

Authors:  Aaron Kandola; Joshua Hendrikse; Paul J Lucassen; Murat Yücel
Journal:  Front Hum Neurosci       Date:  2016-07-29       Impact factor: 3.169

10.  Chronic exposure to haloperidol and olanzapine leads to common and divergent shape changes in the rat hippocampus in the absence of grey-matter volume loss.

Authors:  W R Crum; F Danckaers; T Huysmans; M-C Cotel; S Natesan; M M Modo; J Sijbers; S C R Williams; S Kapur; A C Vernon
Journal:  Psychol Med       Date:  2016-08-12       Impact factor: 7.723

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.